Results 101 to 110 of about 278,902 (273)

Cardiac rhythm devices in heart failure with reduced ejection fraction – role, timing, and optimal use in contemporary practice. European Journal of Heart Failure expert consensus document

European Journal of Heart Failure, EarlyView.
Abstract Guidelines for management of heart failure with reduced ejection fraction (HFrEF) emphasize personalized care, patient engagement, and shared decision‐making. Medications and cardiac rhythm management (CRM) devices are recommended with a high level of evidence. However, there are significant disparities: patients who could benefit from devices
Biykem Bozkurt, Wilfried Mullens, Christophe Leclercq, Andrea M. Russo, Gianluigi Savarese, Michael Böhm, Loreena Hill, Koichiro Kinugawa, Naoki Sato, William T. Abraham, Antoni Bayes‐Genis, Alexandre Mebazaa, Giuseppe M.C. Rosano, Shelley Zieroth, Cecilia Linde, Javed Butler   +15 more
wiley   +1 more source

Complete Cervical Avulsion with Intravaginal Misoprostol for Second Trimester Pregnancy Termination

Case Reports in Obstetrics and Gynecology, 2012
Intravaginal misoprostol, a synthetic PGE1 analogue, has largely replaced all other techniques for pregnancy termination in II trimester, because of its successful results. Incidence of II trimester pregnancy termination has also increased in the present
G. R. Sajjan, Neelamma Patil, Manpreet Kaur, Shobha Shirgur, Suvarna Nandi, V. Ashwini   +5 more
doaj   +1 more source

Minimization or withdrawal of oral pharmacotherapy in chronic heart failure patients with improved myocardial function: A systematic review

European Journal of Heart Failure, EarlyView.
This systematic review included seven studies that reported the outcomes of minimization or withdrawal of oral pharmacotherapy in chronic heart failure (HF) patients with improved myocardial function. There is a dearth of existing evidence, which supports only loop diuretic withdrawal and possibly carvedilol monotherapy.
Yuxiang Luo, Wenbin Xiao, Yusuf Z. Sener, Wouter C. Meijers, Robert M.A. van der Boon, Elfatih A. Hasabo, Osama Soliman, Rudolf A. de Boer, Kadir Caliskan   +8 more
wiley   +1 more source

Heart failure and obesity: Translational approaches and therapeutic perspectives. A scientific statement of the Heart Failure Association of the ESC

European Journal of Heart Failure, EarlyView.
Abstract Obesity and heart failure (HF) represent two growing pandemics. In the general population, obesity affects one in eight adults and is linked with an increased risk for HF. Obesity is even more common in patients with HF, where it complicates the diagnosis of HF and is linked with worse symptoms and impaired exercise capacity. Over the past few
Gianluigi Savarese, Gabriele G. Schiattarella, Felix Lindberg, Markus S. Anker, Antoni Bayes‐Genis, Magnus Bäck, Frieder Braunschweig, Chiara Bucciarelli‐Ducci, Javed Butler, Antonio Cannata, Federico Capone, Ovidiu Chioncel, Emilia D'Elia, Arantxa González, Gerasimos Filippatos, Nicolas Girerd, Jean‐Sébastien Hulot, Carolyn S.P. Lam, Lars H. Lund, Christoph Maack, Brenda Moura, Mark C. Petrie, Massimo Piepoli, Abdullah Shehab, Mehmet B. Yilmaz, Peter Seferovic, Carlo G. Tocchetti, Giuseppe M.C. Rosano, Marco Metra   +28 more
wiley   +1 more source

Wish to conceive and concerns to develop cardiovascular complications during pregnancy in patients with Turner syndrome

Journal of Psychosomatic Obstetrics and Gynecology, 2017
Introduction: Turner syndrome (TS) is associated with subfertility and infertility. Nevertheless, an increasing number of women become pregnant through oocyte donation.
Iris M. van Hagen, Anthonie L. Duijnhouwer, Marianne J. Ten Kate-Booij, Ramon H. M. Dykgraaf, Johannes J. Duvekot, Elisabeth M. W. J. Utens, Jolien W. Roos-Hesselink   +6 more
doaj   +1 more source

Assessing the causal association of pregnancy complications with diabetes and cardiovascular disease

Frontiers in Endocrinology
BackgroundTo the best of our knowledge, numerous observational studies have linked pregnancy complications to increased risks of diabetes and cardiovascular disease (CVD), causal evidence remains lacking. Our aim was to estimate the association of adverse pregnancy outcomes with diabetes and cardiovascular diseases.MethodsA two-sample Mendelian ...
Yuan Xie, Jie Zhang, Shuang Ni, Ji Li
openaire   +3 more sources

The crosstalk between immune activation and metabolism in heart failure. A scientific statement of the Heart Failure Association of the ESC

European Journal of Heart Failure, EarlyView.
Abstract A better understanding of additional mechanisms of heart failure (HF) progression may allow a different and more complete phenotyping of the disease and identification of novel therapeutic targets. Persistent latent myocardial inflammation/immune activation in HF may represent an attempt to restore tissue homeostasis in the failing heart ...
Gabriele Fragasso, Davide Stolfo, Markus S. Anker, Antoni Bayes‐Genis, Ovidiu Chioncel, Stephane Heymans, Pardeep S. Jhund, Basil S. Lewis, Gary D. Lopaschuk, Lars H. Lund, Arantxa Gonzalez, Matteo Pagnesi, Gabriele Giacomo Schiattarella, Carlo Gabriele Tocchetti, Peter van der Meer, Sophie Van Linthout, Sven Wassmann, B. Daan Westenbrink, Marco Metra, Giuseppe M.C. Rosano, Gianluigi Savarese   +20 more
wiley   +1 more source

Immune dysregulation as a key driver of peripartum cardiomyopathy – an exploratory advanced imaging and biomarker study

European Journal of Heart Failure, EarlyView.
Physiological postpartum remodelling and the pathological processes involved in peripartum cardiomyopathy (PPCM). 18FDG‐PET‐CT, 18F‐fluorodeoxyglucose positron emission tomography‐computed tomography; CCL3, chemokine (C‐C motif) ligand 3; CMR, cardiovascular magnetic resonance; CRP, C‐reactive protein; CSF‐1, colony‐stimulating factor 1; CXCL10 ...
Julian Hoevelmann, Charle Viljoen, Tessa Kotze, Carlos Libhaber, Stephen Jermy, Morné Kahts, Fareda Jakoet‐Bassier, Petronella Samuels, Olivia Briton, Lynette Cilliers, Denise Hilfiker‐Kleiner, Peter van der Meer, Michael Böhm, Ntobeko A.B. Ntusi, Karen Sliwa   +14 more
wiley   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons, Marc A. Beal, Kerry L. Dearfield, George R. Douglas, Min Gi, B. Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Michelle Kenyon, Alexandra S. Long, David P. Lovell, Anthony M. Lynch, Meagan B. Myers, Stefan Pfuhler, Alisa Vespa, Andreas Zeller, George E. Johnson, Paul A. White   +17 more
wiley   +1 more source

Postnatal Expression Profile of microRNAs Associated with Cardiovascular and Cerebrovascular Diseases in Children at the Age of 3 to 11 Years in Relation to Previous Occurrence of Pregnancy-Related Complications

International Journal of Molecular Sciences, 2019
Children descending from pregnancies complicated by gestational hypertension (GH), preeclampsia (PE) or fetal growth restriction (FGR) have a lifelong cardiovascular risk.
I. Hromadníková, K. Kotlabova, L. Dvořáková, L. Krofta, J. Širc   +4 more
semanticscholar   +1 more source